Formulation and evaluation of gastro-retentive floating bilayer tablet for the treatment of hypertension

Balaji Maddiboyina a,*, Mudavath Hanumanaika b, Ramya Krishna Nakka la, Vikas Jhawat b, Pinki Rawat c, Aftab Alam d, Ahmed I. Foudah d, Majed M. Alrobaiane e, Rahul Shuklaf f, Sima Singh g, Prashant Kesharwani h,*

a Department of Pharmacy, Vishwabharathi College of Pharmaceutical Sciences, Guntur, Andhra Pradesh, 522009, India
b Department of Pharmacy, School of Medical & Allied Sciences, GD Goenka University, Gurgaon, 122103, India
c Maharana Pratap College of Pharmacy, Kanpur, 209217, Uttar Pradesh, India
d Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 16278, Saudi Arabia
e Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Taif University, Taif, 21974, Saudi Arabia
f Department of Pharmacognosy, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow, 226002, Uttar Pradesh, India
g School of Pharmacy, Sharda University, Greater Noida, Uttar Pradesh, India
h Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India

ARTICLE INFO

Keywords: Bi-layer floating tablets Optimization Superdisintegrants Release-retarding polymers Drug delivery Pharmaceutical science Biomedical engineering Health sciences Public health Cardiology Clinical research

ABSTRACT

The paper aimed to progress an ideal gastro-retentive drug delivery system intended for directing Losartan and Hydrochlorothiazide as a fixed-dose combination for anti-hypertensive therapy. The bilayer tablets were primed through direct compression method. Losartan was formulated by means of a floating layer expending hydrophilic swellable polymer Hydroxy Propyl Methyl Cellulose K4M, ethyl cellulose (4cps) as a buoyancy enhancer, sodium bicarbonate as a gas spawning agent. The amount of polymer blends remains optimized using 2³ full factorial designs. The clout of experimental factors such as swelling agent concentration, buoyancy enhancer and gas generating agent on floating lag time, total floating time, T50% and % drug release remain investigated to get optimized formulation. The responses remain analyzed using Analysis of variance, and polynomial equation stood created for every retort using Multiple linear regression analysis. Entirely preparations floated for more than 12 h. The release pattern of losartan stood fitted to diverse models based on the coefficient of correlation (r). All the formulations, except F2, showed the Korsemeyer-Peppas model as the best fit model. Formulation F2 showed the zero-order model. Diffusion exponents (n) remained indomitable designed for entirely formulations (0.45–0.89), accordingly the chief drug discharge mechanism was non-fickian (anamolous) transport. Formulation F4 containing 20% w/w Hydroxy Propyl Methyl Cellulose K4M, 15% Sodium bicarbonate and 5% ethyl cellulose (4cps) was the best formulation as per the range of drug release remain institute to be more than 95 % in 12h and floating lag time was 20.15 s. The immediate-release layer stood optimized using crospovidone and Indion 414 as a super disintegrant. Formulation A8 containing 2% Indion 414 was considered as optimized formulation as it released 99% drug within 35 min and possessed less disintegration time. Optimized formulation F4 from the controlled-release layer and A8 from immediate-release layer was used to formulate bilayer tablet. The optimized formulation was imperilled to stability reading for three months at 40 °C/75% relative humidity. The stability revision exhibited no substantial alteration in the appearance of tablets, floating characteristics, drug content and in-vitro drug dissolution. Consequently, a biphasic drug release design was effectively accomplished over the formulation of floating bilayer tablets.

* Corresponding author.
** Corresponding author.
E-mail addresses: mbalaji113@gmail.com (B. Maddiboyina), prashantdops@gmail.com (P. Kesharwani).

https://doi.org/10.1016/j.heliyon.2020.e05459
Received 28 August 2020; Received in revised form 27 October 2020; Accepted 4 November 2020
2405-8440/© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

The controlled release drug delivery systems (CDDS) owning the capacity to be engaged in the stomach remain entitled as Gastro Retentive Drug Delivery Systems (GRDDSs), then both retain aid in enhancing the oral precise release of medications through unremittingly discharging drug afore absorption window designed for an extended period. Further being capable to persistently and sustainably release medication towards the small intestinal absorption window, the enhancements delivered since GRDDSs embrace: attaining a further substantial then extended therapeutic outcome and consequently falling the incidence of management epochs, only if further effective management of resident stomach ailments, and curtailing equally lower-tract deactivation of the medication and impacts on the lower intestinal flora. Subsequently that, innumerable methodologies of this sort as floating, bioadhesive, swelling and escalating systems oblige remain advanced toward surge the gastric retaining period of a dosage form [1].

Bilayer tablet remains a novel epoch designed for the effective advance of controlled delivery design laterally through numerous sorts to deliver an approach of efficacious drug transport system [2, 3]. Bi-layer tablet remain seemingly intended for ensuing discharge of two medications in combination, discrete two discordant constituents then similarly designed for sustained discharge tablet in that single layer is immediate release as initial dose and the subsequent layer is the maintenance dose. Bilayer tablet remains enhanced favourable knowledge to overwhelm the inadequacy of the single-layered tablet [4, 5].

Hypertension (HTN) otherwise similarly notorious as high blood pressure (BP), occasionally arterial hypertension, remains a chronic medicinal situation and that the BP in the arteries is upraised. This entails the heart to effort durable than regular to circulate blood over the blood vessels. The BP implicates two extents, systolic and diastolic, that are reliant on either the heart muscle remains constricting (systole) or relaxed (diastole) amid beats. Normal BP is at or beneath 120/80 mmHg. High BP is supposed to remain extant if it is obstinately at or beyond 140/90 mmHg [6, 7].

Losartan potassium (LSP) is a persuasive, vastly precise angiotensin II type 1 (AT1) receptor antagonist through anti-hypertensive action. It remains eagerly absorbed after the gastrointestinal tract through oral bioavailability of around 33% and a plasma elimination half-life extending after 1.5–2.5 h. Subsequent oral management, losartan is hastily absorbed, and formerly roughly 14% of a losartan dose remains metabolized into active carboxylic acid metabolite (E3174) by CYP2C9. E3174 is 10–40 fold further persuasive than owned parent composite, then the probable half-life sorts after 6–9h. Hydrochlorothiazide (HCT) is a thiazide diuretic and is adopted in the supervision of slight to moderate hypertension. It remains precise marginally soluble in water holding a plasma half-life of 6h–14h and protein binding 67.9%. It remains variably absorbed from the gastrointestinal tract, eliminated rapidly by the kidney and primarily excreted in unchanged form in urine [8].

A fixed-dose combination of losartan potassium (LSP)/Hydrochlorothiazide (HCT) remedy might remain a consistent prime for anti-hypertensive management, comprising meant for preliminary remedy in patients with BP elevation >20/10 mmHg beyond management target. Particular adverse effects concomitant with HCT, comprising improved peril designed for new-onset diabetes mellitus, might be equipage by losartan [8]. Losartan remained recurrently managed through HCT in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) revision, in which there stood a 25% peril decline for stroke in the losartan-based paralleled through the atenolol-based supervision group. The efficiency, permissibility, and suitability of Losartan/HCT combination treatment might surge patient amenability and lessen peril for stroke, an unfortunate consequence in patients with hypertension [9].

The combinations of Losartan potassium and Hydrochlorothiazide oblige remain revealed to have an improver outcome on BP decline, reducing BP to a greater mark than either constituent alone. Several pharmacological interactions support the potential further anti-hypertensive benefits from combined therapy with the angiotensin-II receptor (type AT1) antagonist and diuretics. The combined drug is adopted as a fixed-dose permutation to diminish the quantity of medicines [10].

An experimental design stays a statistical strategy, which suggests or instructs a customary of permutation of variables. The numeral and outline of certain design facts inside the pilot section hinge on the quantity of issues such need to be probable. Provisional on the sum of aspects, their intensities, probable interfaces and directive of the exemplar, several experimental designs remain preferred. The most straightforward factorial design remains the two factorial design, in which two aspects are deliberated apiece at two levels, hints to four experiments that remain found in 2-dimensional factor space at the corners of a rectangle. The number of experiments is assumed by 2^n, where ‘n’ is the number of factors [11].

2. Materials and methods

LSP, HCT, HPMC K4M was obtained from SABC Research labs, Hyderabad. CrosPovidone, Indion 414 was procured from HIQ Labs, Hyderabad.

2.1. Compatibility studies of drug and polymers

2.1.1. Fourier transform infrared spectrometry (FTIR)

Approximately 300mg of KBr was weighed and grind to a fine powder, and then approximately 1mg of the Pure drug/combination of drug-excipients was added and grinded well to mix the sample with the KBr and then press this KBr mixer and made a palate by using IR press at the pressure of 8-ton [12].

2.1.2. Differential Scanning Calorimetry (DSC)

The DSC exploration confirmed physical stature of inherent medication esoteric the nanoparticles. The sample remains placed and wrapped typical aluminium pan and was perused between 25 °C to 300 °C with a heating rate of 10°C/minute beneath nitrogen atmosphere. A blank aluminium pan served as reference [13].

2.2. Preparation and optimization of bilayer floating tablets

2.2.1. Formulation of immediate-release tablets of HCT

The medication along with super disintegrants crospovidone/Indion 414, microcrystalline cellulose and lake sunset yellow were weighed and passed through sieve no 60 discretely as displayed in Table 1. The concentration of crospovidone and Indion 414 were 2, 3, 4, 5 % and 0.5, 1, 1.5, 2 % respectively. The admixture of powders remains swayed out by utilizing a pestle and mortar intended for 10 min. Finally, the prepared powder blend lubricated through magnesium stearate and colloidal silicon dioxide then further assorted in mortar pestle for 3 min. The prepared powder blend was manually fed into the 4 mm flat-faced punches and the tablets having a final weight of 50 mg remained primed by direct compression (DC) on ten stations rotary tablet machine (Rimek Mini Press-I) [14].

2.2.2. Preliminary trial batches (PTB) of controlled release floating tablet of losartan

The PTB remain primed by expending hydrophilic polymers HPMC K4M, effervescent agent (sodium bicarbonate) and buoyancy enhancer (ethylcellulose 4 cps) at different concentrations and % CDR, FLT and total floating duration remain patterned and on such premise stages of beyond constituents remain fixed as follows: HPMC K4M: 20 %–30 % w/
2.4. Formulation of bilayer preferred tablets [16].

Controlled release layer was used to formulate bi-layer by tablet punching contrivance through by means of 9.5 mm ated-release layer then improved compression force and then compressed layer’s powder blend of HCT was added over pre-compressed immediate layer of powder. Consequently, immediate-release contrivance and formerly compacted at low compression force to the composite served physically into the dies of 10 stations rotary tablet compression practice accordingly. Initially controlled release powder blend separately. Lots of bilayer tablets remain primed by direct powder blend then 300 mg of controlled-release LSP and HCT. Accurately weighed 50 mg of immediate-release stratum enhancer ethyl cellulose (4 cps) and gas generating agent NaHCO3 remain Losartan potassium, release-retarding polymer HPMC K4M, buoyancy Coded and actual values of X1:- 1 

w, Sodium bicarbonate: 10 % to 15% w/w and Ethylcellulose (4 cps): 5 % to 10 w/w.

2.3. Optimization of LSP using 2³ full factorial designs

By means of 3 factors at 2 levels, full-factorial trials entailing of 8 preparations, remain intended. (2³ = 8) with one extra checkpoint formulation, as shown in Table 2 [15].

2.3.1. Formulation of controlled release floating tablets of LSP

Tablets enclosing 50 mg of LSP was primed, conferring to the intention portrayed in Table 3, by DC. The corresponding powders, explicitly Losartan potassium, release-retarding polymer HPMC K4M, buoyancy enhancer ethyl cellulose (4cps) and gas generating agent NaHCO3 remain conceded over sieve no. 60, distinctly as exhibited in Table 3. Mingling of powders remain conceded out expending a pestle and mortar meant for 10 min. Colloidal silicon dioxide and magnesium stearate remained, formerly auxiliary to the assorted powders. Admixture stood sustained intended for another 3 min. Lastly, 300 mg of respective mixture remain weighed and served physically into the die of a 10 station rotary tablet contrivance, fortified through flat-faced punches (9.5 mm), to result the preferred tablets [16].

2.4. Formulation of bilayer floating tablets

Optimized formulation from the immediate-release layer and controlled release layer was used to formulate bi-layer floating tablet of LSP and HCT. Accurately weighed 50 mg of immediate-release stratum powder blend then 300 mg of controlled-release floating layer powder blend separately. Lots of bilayer tablets remain primed by direct compression practice accordingly. Initially controlled release powder composite served physically into the dies of 10 stations rotary tablet contrivance and formerly compacted at low compression force to the designed uniform layer of powder. Consequently, immediate-release layer's powder blend of HCT was added over pre-compressed immediate-release layer then improved compression force and then compressed by tablet punching contrivance through by means of 9.5 mm flat-faced punch [17].

2.5. Characterization parameters

Appearance: The appearance was acknowledged visually through proving the colour variance.

Hardness: It was measured using Monsanto hardness tester.

Thickness: A Mitutoyo Digital Vernier calliper stood adopted to regulate the thickness of ten arbitrarily designated tablets [18].

Friability: 10 tablets remained arbitrarily designated and employed in the drum of tablet friability check equipment then stood familiar to revolve 100 intervals in 4 min. The tablets remained impassive then precisely balanced. The % weight loss stood ascertained [19].

\[
\% F = \left(1 - \frac{W_f}{W_i}\right) \times 100
\]

where, \(\% F\) = Friability in %, \(W_i\) = Initial wt of tablets, \(W_f\) = Wt of tablets after revolution.

Weight variation: 20 tablets remain randomly designated, the average weight stood ascertainment, and then they remain weighed individually to calculate the standard deviation.

Drug content: 20 tablets remain balanced and crumpled. An extent of powder corresponding to the quantity of single tablet (50 mg) stood accurately weighed and reassigned to 100ml volumetric flask. Volume was prepared up to the streak through methanol in a 100ml volumetric flask then Sonicated intended for 10–15 min. The drug content remain indomitable by UV spectroscopy at a wavelength of 270nm for HCT; 234nm for Losartan potassium [20].

2.5.1. Tablet floating behaviour

Concisely, tablets remain allocated in a glass beaker, carrying 200 mL of 0.1 N HCl, asserted in a water bath at 37 ± 0.5 °C. The floating lag time remains notorious as the time inside tablet prologue and its buoyancy. The entire floating extent the time through that tablet remnant buoyancy remains reported.

2.5.2. Swelling index

The water uptake revision of the tablet stood prepared expending USP dissolution apparatus II. The vehicle adopted remains distilled water, 900 ml revolved at 50 rpm. The vehicle stay retained at 37 ± 0.5 °C through

| Variables | Formulations |
|-----------|--------------|
| X1        | F1, F2, F3, F4, F5, F6, F7, F8, C1 (Check point) |
| X2        | -1, 1, -1, 1, 1, -1, -1, 1, 0 |
| X3        | -1, -1, 1, 1, -1, -1, 1, 1, 0 |

Table 2. Factorial Design Batches of LSP floating tablet.

| Variables | Formulations |
|-----------|--------------|
| X1        | F1, F2, F3, F4, F5, F6, F7, F8, C1 (Check point) |
| X2        | -1, 1, -1, 1, 1, -1, -1, 1, 0 |
| X3        | -1, -1, 1, 1, -1, -1, 1, 1, 0 |

Where X1 = Conc. of HPMC K4M (%), X2 = Conc. of NaHCO3 (%), and X3 = Conc. of Ethyl cellulose (%).

Coded and actual values of X1: -1 = 20, +1 = 30, 0 = 25.

Coded and actual values of X2: -1 = 10, +1 = 15, 0 = 12.5.

Coded and actual values of X3: -1 = 5, +1 = 10, 0 = 7.5.
the revision [21]. Subsequently a designated period interval, the tablets remained introvert, marked to take away surplus water then balanced. Swelling individualities of the tablets remain uttered in rapport of water uptake (WU) as:

$$WU(%) = \frac{\text{Weight of the swollen tablet} - \text{initial weight of the tablet}}{\text{Initial weight of the tablet}}$$

2.5.3. In vitro disintegration test for immediate release HCT tablets

Arbitrarily 6 tablets stood designated from the respective lot for disintegration test. Disintegration test remain accomplished deprived of the disc in simulated gastric fluid (37 + 0.5°C) expending disintegration apparatus.

2.6. In vitro dissolution studies [22]

2.6.1. Immediate release HCT tablets

It stood conceded out on type II apparatus exhausting the paddle. 500 ml of pH 1.2 buffer (0.1N HCl) as dissolution medium at 37 ± 0.5°C through the rotational speediness of 50 rpm. The illustrations remain introvert at a determined time interim up to 40 min and analyzed on UV spectrophotometer at 270 nm.

2.6.2. Controlled-release floating tablets of losartan potassium

It remains conceded out on type II apparatus expending the paddle. 900 ml of pH 1.2 buffer (0.1N HCl) as dissolution medium at 37 ± 0.5°C through a rotational speediness of 50 rpm. The sample stood introvert at scheduled period interval adequate 12h and explored on UV spectrophotometer at 234 nm.

2.6.3. Floating bi-layer tablet of losartan and HCT

Dissolution of the bilayer tablets remain conceded out on type II apparatus expounding a paddle. 900 ml of pH 1.2 buffer (0.1N HCl) as dissolution medium at 37 ± 0.50C with a rotational speediness of 50 rpm. The paddle stood introvert at scheduled period interval adequate 12h and evaluated on UV spectrophotometer by simultaneous estimation method [23].

2.7. Statistical analysis of responses

The Surface response plot, Contour plots were drawn using Design Expert Software v 8.0.6.1 (STATEASE).

2.8. Release kinetics

In edict to apprehend the contrivance and kinetics of drug discharge, the outcomes of the in vitro drug discharge revision stood fitted through innumerable kinetic reckonings namely zero-order (% release vs time), first-order (log% unreleased vs time), and Higuchi matrix (% release vs square root of time). To delineate an exemplary that resolve epitomize a innumerable kinetic reckonings namely zero-order (% release vs time), first-order (log% unreleased vs time), and Higuchi matrix (% release vs square root of time). To delineate an exemplary that resolve epitomize a

the Mt/M∞ is the fraction of drug released at time t, k is the kinetic constant and n is the diffusion exponent, a degree of the principal contrivance of drug discharge. Regression coefficient (r²) values remain contrived for the linear curves acquired by regression exploration of the beyond plots [24].

2.9. Stability studies

Stability application of the enhanced preparation remains conceded out as conferring to the ICH recommendations, at 40 ± 2 °C/75 ± 5% RH by adopting Thermolab TH 905 stability chamber for 3 months. The carried remain observed for drug content, floating behaviour and in vitro drug release profile [25].

3. Results & discussion

3.1. Compatibility studies of drug and polymers

3.1.1. Fourier transform infrared spectrometry (FTIR)

It was found that there was no possible interaction in between drug and super disintegrants in their original form and mixture form as displayed in Figure 1.

3.1.2. Differential Scanning Calorimetry (DSC)

Compatibility examinations stood similarly conceded by using DSC, which is a qualitative analytical tool for assessing the interactions. The thermograms indicated no significant change in drug endotherm peaks in mixture samples, as shown in Figure 2.

3.2. Preparation and optimization of bilayer floating tablets

The contemporary concerns was carried out to advance a bilayer floating drug release practice of LSP and HCT to augment absorption and bioavailability through amassed the gastric retention period of the drug. In apprehension towards this method, the crucial requisite remains to float the tablet in a gastric environs and further proceedings for the development of floating bilayer tablets.

Preformulation study remain toted out expending different concentration level of HPMC K4M, Sodium bicarbonate and Ethylcellulose (4cps) for floating layer and Crospovidone and Indion 414 for immediate release layer to optimize the formulations. The criteria for selection of optimum immediate-release tablet were in vitro disintegration period and in vitro drug delivery. Eight formulations remain prepared using different concentration of Crospovidone (A1-A4) and Indion-414 (A5-A8). Formulation A8 containing 2% of Indion 414 was optimized formulation.

3.3. Optimization of LSP using 2³ full factorial design

A full factorial 2³ = 8 experiments were designed with one extra checkpoint formulation. Optimization of the HBS system was made based on 3 dependent variables viz: i) Drug release at 12h ii) time required to 50% of drug discharge iii) Floating lag time. The preparations were
studied for the effect of concentration of swelling agent (HPMC K4M), the concentration of gas spawning agent (Sodium bicarbonate) and buoyancy enhancer (ethylcellulose 4cps) on the dependent variables (response). To know the effect of each variable on the responses, the variables and responses were selected for the Analysis of Variance (ANOVA) and multiple linear regression analysis. Formulation F4 containing 20% of HPMC K4M, 15% sodium bicarbonate and 5% of ethyl cellulose was optimized formulation.

3.4. Formulation of bilayer floating tablets

Optimized formulation A8 from the immediate-release layer and F4 from the floating layer was used for the formulation of the bilayer tablet. Direct compression method employed for all formulations was found to be satisfactory for instance the physicochemical evaluation constraints remained inside the permissible limits.

3.5. Characterization parameters

3.5.1. Characterization parameters for immediate release tablets of HCT

The thickness of the prepared tablet is in the range of 2.523 ± 0.036 to 2.736 ± 0.019mm. The hardness of the formulated tablets remain institute in the array of 3.4–3.8 kg/cm². The friability of all the tablets remain institute to be less than 1%, i.e. in the array of 0.231%–0.426% as displayed in Table 4. The formulation A8 shows lowest disintegration time 11.27 s because of its swelling tendency on wetting.

Figure 1. FTIR spectrum of (a) pure LSP (b) pure HCT (c) HCT + Crospovidone + MCC + Magnesium stearate + Colloidal silicon dioxide + Lake sunset yellow (D) HCT + Indion 414 + MCC + Magnesium stearate + Colloidal silicon dioxide + Lake sunset yellow (E)Losartan Potassium + HPMC K4M + Ethyl cellulose + Sodium bicarbonate + MCC + Magnesium stearate + Colloidal silicon dioxide (F) LSP + HCT + HPMC K4M + Ethyl cellulose + Sod bicarbonate + Indion 414 + MCC + Magnesium stearate + Colloidal silicon dioxide + Lake sunset yellow.
3.5.2. Characterization parameters for floating tablets of LSP

The thickness of the prepared tablet remains in the range of 3.908 ± 0.046 to 3.988 ± 0.051 mm. The hardness of the formulated GRDDS of Losartan remains institute in the range of 5.2 – 5.6 kg/cm². The friability of entire tablets remain institute to be less than 1%, i.e. in the array of 0.205% – 0.419% as displayed in Table 5.

3.5.2.1. Tablet floating behaviour. The exploration discloses that entire preparations retain good floating effects. The order of floating lag period remains institute to be: F3 < F4 < F7 < F1 < F5 < C1 < F8 < F2 < F6.

3.5.2.2. Swelling index. The swelling index remains extending in amid 50.59 % – 79.13 % as displayed in Table 6. High level of HPMC K4M

**Table 4. Evaluation parameters for immediate release tablets of HCT.**

| Formulation code | Evaluation parameters |
|------------------|-----------------------|
|                  | Thickness ± S.D. (mm) (n = 10) | Hardness ± S.D.(kg/cm²) (n = 5) | Friability (%) (n = 10) | Avg. weight variation (n = 20) | Drug content (%) | Disintegration time (in sec) (n = 6) |
| A1               | 2.544 ± 0.064          | 3.5 ± 0.2                      | 0.412 ± 0.7             | 48.6 ± 2.065              | 99.24            | 25.24 ± 1.96                       |
| A2               | 2.586 ± 0.016          | 3.4 ± 0.3                      | 0.231 ± 0.3             | 49.1 ± 1.48              | 98.42            | 20.16 ± 2.03                       |
| A3               | 2.661 ± 0.054          | 3.8 ± 0.2                      | 0.425 ± 0.5             | 51.23 ± 2.54             | 99.34            | 17.36 ± 1.89                       |
| A4               | 2.523 ± 0.040          | 3.8 ± 0.1                      | 0.323 ± 0.6             | 50.69 ± 1.64             | 97.22            | 13.41 ± 2.66                       |
| A5               | 2.731 ± 0.036          | 3.7 ± 0.2                      | 0.351 ± 0.7             | 51.06 ± 2.70             | 99.13            | 22.38 ± 2.21                       |
| A6               | 2.677 ± 0.012          | 3.6 ± 0.4                      | 0.411 ± 0.4             | 49.95 ± 2.70             | 99.65            | 18.52 ± 2.33                       |
| A7               | 2.736 ± 0.019          | 3.5 ± 0.3                      | 0.365 ± 0.3             | 51.63 ± 2.70             | 98.23            | 14.39 ± 2.065                      |
| A8               | 2.523 ± 0.036          | 3.5 ± 0.5                      | 0.426 ± 0.6             | 47.96 ± 2.70             | 98.59            | 11.27 ± 2.12                       |

3.5.2. Characterization parameters for floating tablets of LSP

The thickness of the prepared tablet remains in the range of 3.908 ± 0.046 to 3.988 ± 0.051 mm. The hardness of the formulated GRDDS of Losartan remains institute in the array of 5.2–5.6 kg/cm². The friability of entire tablets remain institute to be less than 1%, i.e. in the array of 0.205%–0.419% as displayed in Table 5.
and HCT.

and releases more than 99% drug in 35 min as exhibited in Table 7 and optimized formulation by way of it disintegrates very swiftly in 11.27 s. Indion 414 in the concentration of 2% remain designated as per the integrants was compared. Therefore, formulation A8 having disintegrant 3.6. In vitro dissolution studies

Figure 3A. Thus batch A8 of an immediate-release layer and batch F4 of the floating layer was used to formulate bilayer floating tablets of LSP and HCT.

exhibited maximum water uptake, indicated the extreme swelling property. The concentration of NaHCO₃ improved commencing 10%–15% swelling index remain amplified owing to an upsurge in degree of pore development then subsequently, swift hydration of the tablet milieus.

3.6. In vitro dissolution studies

The dissolution contour of the preparations containing both the disintegrants was compared. Therefore, formulation A8 having disintegrant Indion 414 in the concentration of 2% remain designated as per the optimized formulation by way of it disintegrates very swiftly in 11.27 s and releases more than 99% drug in 35 min as exhibited in Table 7 and Figure 3A. Thus batch A8 of an immediate-release layer and batch F4 of the floating layer was used to formulate bilayer floating tablets of LSP and HCT.

Formulæ F4 containing the highest gas-forming agent concentrations and lowest HPMC K4M concentration showed the highest drug release, as shown in Table 8 and Figure 3B. These release revisions exposed that the imperative of release remained institute to exist F4>F3>F1>C1>F7>F8>F5>F6>F2.

3.7. Statistical analysis of responses

Multiple linear regression analysis was performed for dependent variables Q12, FLT and T50% as shown in Figure 4. The most significant coefficient means the causal factor has a more potent influence on the response. The values of the correlation coefficient for Q12, FLT and T50% are 0.9996, 0.9995 and 0.9189, respectively. The above concentration of ingredients was almost the same as the value of factorial batch F4 formulation. Consequently, batch F4 remained desirable by means of the optimized batch, as shown in Figure 5.

Table 5. Evaluation parameters for floating tablets of Losartan Potassium.

| Formulation code | Evaluation parameters |
|------------------|-----------------------|
|                  | Thickness (mm) ±S.D. (n = 10) | Hardness (kg/cm²) ±S.D. (n = 5) | Friability (%) (n = 10) | Avg. weight variation (n = 20) | Drug content (%) |
| F1               | 3.94 ± 0.093           | 5.2 ± 0.4                           | 0.29 ± 0.5               | 302 ± 0.011                  | 97.29            |
| F2               | 3.908 ± 0.046          | 5.4 ± 0.2                           | 0.308 ± 0.4              | 298 ± 0.100                  | 98.41            |
| F3               | 3.934 ± 0.035          | 5.3 ± 0.2                           | 0.410 ± 0.6              | 365 ± 0.018                  | 97.16            |
| F4               | 3.941 ± 0.023          | 5.6 ± 0.1                           | 0.152 ± 0.7              | 304 ± 0.013                  | 99.63            |
| F5               | 3.962 ± 0.048          | 5.5 ± 0.6                           | 0.419 ± 0.6              | 295 ± 0.014                  | 98.17            |
| F6               | 3.956 ± 0.039          | 5.5 ± 0.3                           | 0.244 ± 0.5              | 304 ± 0.009                  | 97.24            |
| F7               | 3.968 ± 0.051          | 5.2 ± 0.2                           | 0.298 ± 0.3              | 299 ± 0.021                  | 99.92            |
| F8               | 3.928 ± 0.025          | 5.5 ± 0.3                           | 0.205 ± 0.5              | 308 ± 0.111                  | 99.52            |
| C1               | 3.964 ± 0.058          | 5.4 ± 0.4                           | 0.393 ± 0.4              | 304 ± 0.015                  | 98.64            |
| Bilayer FT       | 4.62 ± 0.055           | 5.4 ± 0.2                           | 0.244 ± 0.5              | 348 ± 0.009                  | 98.23 (LSTN) 99.48 (HCT) |

Table 6. Results of the floating property of the losartan floating tablets.

| F. Code | Floating lag time (sec) | Total floating time (Hr) | % Swelling Index | T 50% (Hr) |
|---------|------------------------|--------------------------|-----------------|------------|
| F1      | 30.32 ± 0.8            | >12                      | 46.57 ± 0.012   | 6.214      |
| F2      | 58.25 ± 0.9            | >12                      | 63.1 ± 0.018    | 9.286      |
| F3      | 13.64 ± 0.5            | >12                      | 59.52 ± 0.014   | 4.315      |
| F4      | 20.15 ± 0.4            | >12                      | 63.54 ± 0.021   | 4.169      |
| F5      | 48.31 ± 0.5            | >12                      | 79.13 ± 0.0135  | 7.296      |
| F6      | 66.39 ± 0.4            | >12                      | 67.21 ± 0.04    | 7.539      |
| F7      | 23.54 ± 0.6            | >12                      | 50.59 ± 0.036   | 7.124      |
| F8      | 56.81 ± 0.5            | >12                      | 74.92 ± 0.0163  | 7.164      |
| C1      | 49.26 ± 0.4            | >12                      | 62.85 ± 0.0132  | 6.638      |
| Bilayer FT | 24.26 ± 0.5          | >12                      | --             | --         |

Table 7. In vitro drug release study for HCT immediate-release tablets.

| Time (min) | A1       | A2       | A3       | A4       | A5       | A6       | A7       | A8       |
|------------|----------|----------|----------|----------|----------|----------|----------|----------|
| 3          | 10.906   | 20.555   | 24.356   | 27.280   | 21.140   | 39.859   | 42.743   | 55.935   |
| 5          | 37.296   | 34.659   | 46.965   | 51.066   | 35.538   | 42.570   | 65.422   | 59.856   |
| 10         | 44.621   | 45.50018 | 63.958   | 66.594   | 40.226   | 47.844   | 69.524   | 63.372   |
| 15         | 48.137   | 57.512   | 73.040   | 76.536   | 58.684   | 63.372   | 71.575   | 77.435   |
| 20         | 57.512   | 78.900   | 79.779   | 82.708   | 61.321   | 65.715   | 75.677   | 81.244   |
| 25         | 70.696   | 85.638   | 87.396   | 89.154   | 64.837   | 67.766   | 78.021   | 90.619   |
| 30         | 75.970   | 89.447   | 90.912   | 92.670   | 67.180   | 71.282   | 80.951   | 95.307   |
| 35         | 79.486   | 90.033   | 92.963   | 96.772   | 70.989   | 78.021   | 83.880   | 99.701   |
| 40         | 87.689   | 90.619   | 96.479   | 98.822   | 75.091   | 83.880   | 90.619   | --       |
| 45         | 96.479   | 98.530   | 98.237   | 99.547   | 84.759   | 90.619   | 98.822   | --       |
A checkpoint lot remains primed at X1 = 0 level, X2 = 0 level and X3 = 0 level as displayed in Table 9, indicates the results of checkpoint batch. From the equation generated from regression analysis by putting the values of X1, X2 and X3 in percentage it remains probable such the significance of Q12 of the checkpoint batch ought to be 79.88 %, the value of FLT of the checkpoint batch ought to be 39.66 s and T 50% of checkpoint batch ought be 6.629h. The outcomes achieved with checkpoint batch are precise adjacent to expected values. Consequently, we can accomplish which the statistical exemplary remains mathematically expedient.

3.8. For floating bilayer tablets

Composition of bilayer floating tablet includes an immediate-release layer (A8 Batch) and controlled release floating layer (F4 Batch) as exhibited in Table 10. The average weight, thickness and hardness of primed tablet remain institute to exist 348mg, 4.62 mm and 5.4 kg/cm² correspondingly. The drug content of the primed bilayer tablets remain establish to be 98.23 (LSP) and 99.48 (HCT). The In vitro drug release of the primed bilayer tablets remains institute to stay 97.32% (LSP for 12h) and 98.56% (HCT in 35 min).

3.9. Release kinetics

The results ascertained such the release mechanism for LSP floating tablets remained by diffusion and swelling controlled mechanism, i.e. Non-fickian/anomalous transport where n value lies amid 0.45 to 0.89 for entire preparations as displayed in Table 11. From the ‘n’ value of optimized formulation (0.560) acquired it can remain assumed that the diffusion charted Non-fickian mechanism and from regression coefficient value (0.9851) it can be said that it follows Peppas model for drug release.

3.10. Stability studies

Stability study was performed for optimized floating bilayer tablet formulation at 40 ± 10C and RH 75% for 3 months. The illustrations remain examined for hardness, percent drug content, floating behaviour

### Table 8. In-vitro drug release study for Losartan floating tablets.

| Time (Hr) | F1  | F2  | F3  | F4  | F5  | F6  | F7  | F8  | C1  |
|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 0.5       | 9.75| 5.908| 15.054| 16.701| 4.993| 4.335| 7.554| 8.103| 10.298|
| 1         | 16.353| 9.394| 24.044| 25.143| 10.859| 10.310| 13.844| 14.155| 17.452|
| 2         | 25.510| 13.331| 32.835| 33.567| 16.902| 17.269| 19.832| 19.649| 24.594|
| 3         | 33.384| 17.234| 40.526| 41.259| 22.579| 24.411| 24.411| 24.960| 29.538|
| 4         | 37.596| 20.565| 46.936| 49.316| 26.975| 31.187| 30.820| 30.271| 35.215|
| 5         | 43.273| 24.960| 54.261| 53.345| 34.117| 36.131| 36.314| 35.765| 40.892|
| 6         | 48.584| 28.440| 60.854| 59.755| 42.357| 42.907| 42.907| 42.174| 45.104|
| 7         | 55.177| 35.9483| 65.798| 65.798| 48.218| 46.936| 48.950| 48.584| 54.261|
| 8         | 60.487| 41.442| 70.926| 71.658| 56.092| 52.613| 57.374| 57.191| 60.671|
| 9         | 67.992| 47.851| 76.237| 76.237| 61.586| 56.092| 63.234| 62.502| 65.249|
| 10        | 72.941| 55.360| 80.815| 84.477| 66.348| 59.938| 70.743| 70.010| 72.208|
| 11        | 80.815| 59.938| 85.759| 90.154| 70.743| 64.516| 76.603| 75.870| 76.603|
| 12        | 85.759| 64.334| 90.154| 95.465| 74.772| 69.278| 80.449| 79.350| 81.547|
and in-vitro drug release revisions. The results are given in Table 12. No substantial variance was perceived for the beyond parameters.

4. Discussion

An effort remained thru to upsurge the oral bioavailability of Losartan and Hydrochlorothiazide fixed-dose combination through retentive the dosage form in the stomach intended for a more extended epoch. This remains accomplished by evolving a gastroretentive floating drug delivery system. The precise tablets remain primed to surge the bioavailability of the medications by employing the medications to a complete degree evading avoidable incidence of dosing and consequently the first-pass metabolism.

Losartan and Hydrochlorothiazide combination indicated for hypertension with left ventricular hypertrophy adults. Losartan was having a plasma elimination half-life extending after 1.5–2.5h with oral bioavailability of about 33% needs gastro-retention to improve bioavailability and to evade the first-pass consequence, on the other hand, Hydrochlorothiazide having a half-life of 8 h–14 h with 67.9 % protein binding needs immediate release. To achieve patient compliance by controlling blood pressure for an extended duration of time, a floating bilayer tablet of this fixed-dose combination was suggested.

For the formulation of bilayer floating tablets floating as well as immediate release layers were optimized separately. Crospovidone and Indion 414 were used as super disintegrants. HPMC K4M stood practiced as matrix creating gelling agent. Ethylcellulose adopted as a buoyancy enhancer and release retardant. Other excipients used were MCC (Diluent), NaHCO₃ (gas generating agent), Magnesium stearate (lubricant) and colloidal silicon dioxide (glidant). FTIR and DSC thermograms inveterate the nonappearance of any drug/polymers/excipients interfaces. A physical mixture of medication and polymer were considered by FTIR spectral exploration designed for every physical along with chemical disparity of the medication. From the outcomes, it remain determined that there existed no interfering in the functional groups as the principal peaks of the Losartan and Hydrochlorothiazide remain institute to be intact, designating they stood compatible chemically. Compatibility studies were also carried by using DSC, which is a qualitative analytical tool for assessing the interactions. The thermograms indicated no substantial amendment in drug endotherm peaks in mixture samples. However, the change in shape and alterations in drugs mixture peak was related to the absorbed moisture by the samples.

Direct compression practice remains engaged to articulate the tablets, since of its cost-clout and owing to reducing the sum of developed strides.

Figure 4. 3D Response Surface plot showing the effect of factorial variables on: A, B- % CDR at 12h; C, D- Floating lag time; E, F- T 50%.
The prepared floating tablet, immediate-release tablet and bilayer tablets remain assessed for hardness, weight variation, thickness, friability, drug content uniformity, in vitro disintegration time, buoyancy lag time, total floating time, water uptake (swelling index), in-vitro dissolution studies. The order of floating lag time remain found to be F3 < F4 < F7 < F1 < F5 < C1 < F8 < F2 < F6. The above results showed such upsurge in the concentration of HPMC K4M upsurges of floating lag time because at high-level HPMC K4M intend perhaps prevent the admittance of medium under the tablet matrix and persist the floating lag period. As proportions of NaHCO₃ upsurges, the floating lag period declines. This spectacle influence is owing to the bearing of more massive extents of effervescence through greater NaHCO₃ proportions. This intend prime to an upsurge in the degree of pore development then subsequently, swift hydration of the tablets matrices. The above order of results showed such upsurge in the concentration of ethyl cellulose results in a decline of floating lag period since of its little bulk density.

The swelling index showed the utmost water uptake, revealed the extreme swelling property. The capacity of hydrogels to engross water is owing to the existence of hydrophilic groups. The hydration of the particular functional groups outcomes in water admittance towards the polymer matrix prominent to extension then subsequently an assembling of the polymer chains.

Entire preparations remain imperilled to five diverse models viz. Zero-order, First order, Higuchi matrix, Peppas model and Hixson-Crowell equations and all the formulations followed Peppas model. The curve fitting consequences of discharge degree contours for the

| Formulation code | Variable levels in coded form | T₅₀% (Hours) | % CDR in 12h (Q12) | Floating Lag time (Sec) |
|------------------|-------------------------------|-------------|-------------------|------------------------|
|                  | X₁   | X₂   | X₃   |               |                      |                      |
| F1               | -1   | -1   | -1   | 6.214          | 85.75                 | 21.26                 |
| F2               | +1   | -1   | +1   | 9.286          | 64.33                 | 34.32                 |
| F3               | -1   | +1   | +1   | 4.315          | 90.15                 | 9.62                  |
| F4               | -1   | +1   | -1   | 4.169          | 95.46                 | 14.56                 |
| F5               | +1   | +1   | -1   | 7.226          | 74.77                 | 27.13                 |
| F6               | +1   | -1   | -1   | 7.539          | 69.27                 | 39.65                 |
| F7               | -1   | -1   | +1   | 7.124          | 80.44                 | 16.23                 |
| F8               | +1   | +1   | -1   | 7.164          | 79.35                 | 35.89                 |
| C1               | 0    | 0    | 0    | 6.638          | 81.54                 | 41.24                 |

Table 9. Dissolution Parameters for 2³ Full Factorial Design formulations.

Table 10. Comparison of the observed value and predicted value for checkpoint formulation C1 and optimized formulation F4.

| Responses | Predicted value | Observed value | % Deviation |
|-----------|----------------|----------------|-------------|
|           | C1  | F4  | C1  | F4  | C1  | F4  |           |
| Q12       | 79.88 | 95.001 | 81.54 | 95.46 | 0.96 | 0.459 |           |
| FLT       | 39.66 | 21.2115 | 41.24 | 20.15 | 1.58 | 0.0615 |           |
| T50%      | 6.629 | 4.266 | 6.638 | 4.169 | 0.009 | 0.097 |           |

Figure 5. Numerical optimization Solution Tool Ramps.
premeditated preparations remain imperilled for data exploration expending PCP-V2 dissolution software. It remains institute that entire the preparations stood fitted into Korsemeyers-Peppas model, which remains the best-fitted model.

The floating, immediate and bilayer tablets were compressed using 9.5mm, 4mm, 9.5mm circular flat-faced punches using RIMEK I multi-station rotary punching machine. Floating property revision exposes that all formulations had suitable floating property. All the formulation floats for more than 12h because the gel layers, designed through the probed polymers, facilitated proficient entrapment of the engendered gas bubbles. Upsurge in concentration of HPMC K4M results in the rise of floating lag time because at high-level HPMC K4M exert probably prevent the access of ways towards the tablet matrix then extend the floating lag period.

As the percentage of NaHCO3 upsurges, the floating lag time declines. This spectacle potency is owing to the procreation of more significant extents of effervescence through advanced NaHCO3 proportions. This prime effect to an upsurge in proportion of aperture development then subsequently, swift hydration of the tablets matrices. The above order of results revealed that upsurge in the concentration of ethyl cellulose results in the decline of floating lag period since of its low bulk density. The capacity of hydrogels to captivate water remains owing to the existence of hydrophilic groups. The hydration of the particular functional group outcomes in water admittance towards the polymer complex prominent to extension then accordingly an assembling of the polymer chains.

Based on various evaluation parameters formulation, F4 and A8 were selected as a composition for bilayer floating tablet and was further subjected to in vitro release revision, and stability study. The optimized bilayer floating tablet indicated good stability and values remain inside permitted limits.

5. Conclusion

The strategy of two diverse release phases keep is certainly familiar in together delivery degree and the proportion of the dosage fractions, bestowing to the pharmacokinetics and therapeutic prerequisites. In the immediate-release layer, Indion 414 has a potent effect on in vitro disintegration and in vitro drug discharge. The result of 2² full factorial design discovered such as the HPMC K4M, NaHCO3 and ethyl cellulose concentrations alluringly distress the responses, % CDR, FLT, % Swelling index and T 50%. From the result, it was determined that through assuming a systematic preparation advent, conveyance of two drugs out of a distinct dosage practice could be acquired that might expand bioavailability, patient compliance then provide restored disease supervision.

Declarations

Author contribution statement

P. Kesharwani: Analyzed and interpreted the data; Wrote the paper.
B. Maddiboyina and M. Hanumanaik: Conceived and designed the experiments; Performed the experiments.
R.K. Nakkala and V. Jhawat: Performed the experiments.
A. Alam, A.I. Foudah and P. Rawat: Analyzed and interpreted the data.
M.M. Alrobaian: Conceived and designed the experiments; Contributed reagents, materials, analysis tools or data.
R. Shukla: Performed the experiments; Contributed reagents, materials, analysis tools or data.
S. Singh: Performed the experiments; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of interests statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

[1] P. Mathur, K. Saroha, N. Syan, S. Verma, S. Nanda, V. Valecha, An overview on recent advancements and developments in gastroretentive buoyant drug delivery system, Pharm. Sin. (2011).

Table 11. Kinetic data of various models for release study.

| F. code | Zero order | First order | Matrix | Peppas | Hixon Crowell | Best fitting model |
|---------|------------|-------------|--------|--------|--------------|--------------------|
|         | R k        | R k         | R k    | R k n  | R k          |                    |
| F1      | 0.9802     | 0.0183      | 0.9803 | 0.0002 | 0.9737       | 0.0526             |
| F2      | 0.9953     | 0.0127      | 0.9953 | 0.0001 | 0.9217       | 0.0356             |
| F3      | 0.9336     | 0.0207      | 0.9338 | 0.0002 | 0.9953       | 0.0603             |
| F4      | 0.9516     | 0.0211      | 0.9518 | 0.0002 | 0.9818       | 0.0611             |
| F5      | 0.9965     | 0.0159      | 0.9965 | 0.0002 | 0.9467       | 0.0451             |
| F6      | 0.9871     | 0.0150      | 0.9871 | 0.0001 | 0.9664       | 0.0429             |
| F7      | 0.9952     | 0.0169      | 0.9953 | 0.0002 | 0.9506       | 0.0479             |
| F8      | 0.9943     | 0.0167      | 0.9943 | 0.0002 | 0.9516       | 0.0474             |
| F9      | 0.9807     | 0.0176      | 0.9807 | 0.0002 | 0.9722       | 0.0505             |

Table 12. Results for stability studies of optimized formulation.

| Time (Month) | Evaluation parameters | Drug content (%) | Floating behaviour | CDR (%) |
|--------------|-----------------------|------------------|--------------------|---------|
|               | Hardness (kg/cm²) | LSP (%) | HCT (%) | FLT (sec) | TFT (h) | LSP (%) | HCT (%) |
| 0             | 5.4                  | 98.23 | 99.48 | 24.26 | >12 | 97.32 | 98.56 |
| 1             | 5.3                  | 97.76 | 99.12 | 26.34 | >12 | 97.13 | 98.23 |
| 2             | 5.3                  | 97.29 | 98.86 | 27.23 | >12 | 96.96 | 98.16 |
| 3             | 5.2                  | 97.25 | 98.49 | 28.68 | >12 | 96.84 | 98.09 |
[2] M.I. Tadros, Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: development, optimization and in vitro-in vivo evaluation in healthy human volunteers, Eur. J. Pharm. Biopharm. (2016).
[3] M. Imran, N.M. Ranja, R.K. Ayoub, Controlled-release low density effervescent floating matrix tablets of risperidone: development, optimization, in vitro-in vivo evaluation in healthy human volunteers and determination of dissolution equivalence, Iran. J. Pharmocul. Sci. (2013).
[4] B.Y. Maddina, G.S. Asthana, A. Asthana, Formulation and development of polysaccharide-based nanoconjugates for efficient and targeted drug delivery in cancer treatment, in: Polysacch. Carriers Drug Deliv, 2019.
[5] NCD Risk Factor Collaboration (NCD-RisC), Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants, Lancet (2017).
[6] H. Siddam, N. Kota, B. Maddiboyina, S. Singh, O. Sunnapu, A. Kumar, D. Sharma, Formulation and evaluation of atenolol floating bioadhesive system using optimized polymer blends, Int. J. Pharm. Investig. (2016).
[7] M. Mujahid, S. Baboota, J. Ali, Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of losartan and hydrochlorothiazide in pharmaceutical dosage form and comparison of the results by ANOVA, Res. J. Pharm. Technol. (2019).
[8] R. Tiwari, A. Gupta, M. Joshi, G. Tiwari, Bilayer tablet formulation of metformin HCl and acarbose: a novel approach to control diabetes, PDA J. Pharm. Sci. Technol. (2014).
[9] J.R. Madan, A. Avachat, S. Banode, M. Dangi, Formulation and evaluation of a bilayer floating drug delivery system of nizatidine for nocturnal acid breakthrough, Am. Pharm. (2012).
[10] B. Williams, N.R. Poulter, M.J. Brown, M. Davis, G.T. McIntee, J.F. Potter, P.S. Sever, S. McG Thom, British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, J. Hum. Hypertens. (2004).
[11] B.B. Alshehri, V. Kulkarni, S.M. Alshehri, B.K. Almutairy, E.A. Ashour, J.T. Morott, Formulation and development of bilayer floating tablets of captopril, Acta Pharm. (2006).
[12] S. Singh, H. Vardhan, N.G. Kota, B. Maddiboyina, D. Sharma, T.J. Webster, The role of surfactants in the formulation of elastic liposomal gels containing a synthetic opioid analgesic, Int. J. Nanomed. 11 (2016).
[13] B. Maddiboyina, V. Jhawat, G. Sivaraman, O.P. Sunnapu, R.K. Nakkala, M.H. Naik, N.G. Kotla, S. Singh, B. Maddiboyina, O. Sunnapu, T.J. Webster, A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon specific drug delivery system: an approach to alternative colon media, Int. J. Nanomed. (2016).
[14] Z. Rahman, M. Ali, R. Khar, Design and evaluation of bilayer floating tablets of captopril, Acta Pharm. (2006).
[15] S. Singh, H. Vardhan, N.G. Kota, B. Maddiboyina, D. Sharma, T.J. Webster, The role of surfactants in the formulation of elastic liposomal gels containing a synthetic opioid analgesic, Int. J. Nanomed. 11 (2016).
[16] S. Corveleyn, J.P. Remon, Formulation and in-vitro evaluation of rapidly disintegrating tablets using hydrochlorothiazide as a model drug, Int. J. Pharm. (1997).
[17] A. Divya, K. Kavitha, M. Rupesh Kumar, S. Dakshayani, S.D. Jagadeesh Singh, Bilayer tablet technology: an overview, J. Appl. Pharmaceut. Sci. (2011).
[18] R. Tiwari, A. Gupta, M. Joshi, G. Tiwari, Bilayer tablet formulation of metformin HCl and acarbose: a novel approach to control diabetes, PDA J. Pharm. Sci. Technol. (2014).
[19] J.R. Madan, A. Avachat, S. Banode, M. Dangi, Formulation and evaluation of a bilayer floating drug delivery system of nizatidine for nocturnal acid breakthrough, Am. Pharm. (2012).
[20] R.N. Chen, H.O. Ho, C.Y. Yu, M.T. Sheu, Development of swelling/float gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism, Eur. J. Pharmaceut. Sci. (2010).
[21] B. Maddiboyina, A. Asthana, G.S. Asthana, S. Singh, M. Ramya, O. Sunnapu, N. Kota, Formulation and characterization of polycarbophil coated mucoadhesive microspheres of repaglinide, J. Pharmaceut. Sci. Res. (2015).
[22] K Palasamy SA Mookkandi, G. Sivaraman, B. Maddiboyina, J. Annaraj, J. Rajesh, R. Gururamsy, A novel curcumin-loaded PLGA micromagnetic composite system for controlled and pH-responsive drug delivery, Colloid. Surface. Physicochem. Eng. Aspect. (2019).
[23] O.I. Corrigan, B.A. Heelan, Characterization of drug release from diltiazem-loaded polylactide microspheres prepared using sodium caseinate and whey protein as emulsifying agents, J. Microencapsul. (2001).
[24] R. Lobenberg, J.S. Kim, G.L. Amidon, Pharmacokinetics of an immediate release, a floating drug delivery system of diltiazem in dogs, Eur. J. Pharm. Biopharm. (2005).
[25] S. Niazí, Stability testing of new drug substances and products, in: Handb. Pharm. Manuf. Formul., 2009.